ArticleHealth science reports2025
The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Acute myeloid leukemia (AML) is the most common acute leukemia, which is associated with high morbidity and mortality, and its incidence rate is increasing. Despite tremendous advancements in AML treatment, managing the condition is still challenging. Receptor kinase inhibitors like sorafenib have recently raised concerns about monotherapy, and combination treatments are now being investigated as a potential therapeutic avenue. To classify medications taken in conjunction with sorafenib and analyze their combined effects, we reviewed the prior research findings. Methods: A thorough literature search utilizing several databases, including PubMed, Google Scholar, Scopus, Embase, and Cochrane, yielded 78 relevant articles until October 2023. Search terms including AML, combination, and Sorafenib were utilized during the database search to find relevant papers. Results: Complete remission (CR) in the combination of sorafenib with "cytarabine and idarubicin", "Vorinostat and Bortezomib, Clofarabine", "Fludarabine and Busulfan", "5-azacytidine" and "Quizartinib, Midostaurin and Giltertinib" respectively "99% and 94%", "27% and 3%", 66.6%, "45%, 26%, 16%", "71% and 52%". Furthermore, the overall survival (OS) values for the combination of sorafenib with "Quizartinib, Midostaurin, and Giltertinib", "cytarabine, daunorubicin" and "5-azacitidine" were "80%" "62% 45%", and 24%, respectively. Conclusion: Accordingly, several studies suggest that sorafenib's anticancer effectiveness may be enhanced with chemotherapy drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.